Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2,Condition 3a,Condition 3b,Condition 4 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0002074,N:HS,both,104 days to 97 days,20,,CMO:0001045,number of periods of voluntary immobility,,,,257.49,,10.2926,46.03,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68368,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000663,RHA/N,both,104 days to 97 days,19,,CMO:0001045,number of periods of voluntary immobility,,,,86.6,,7.6854,33.5,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68369,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000671,RLA/N,both,104 days to 97 days,18,,CMO:0001045,number of periods of voluntary immobility,,,,263.2,,7.8017,33.1,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68370,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0002074,N:HS,both,104 days to 97 days,20,,CMO:0001037,time to first movement outside a discrete space in an experimental apparatus,,following stimulus,,14.32,s,1.2433,5.56,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68362,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000663,RHA/N,both,104 days to 97 days,19,,CMO:0001037,time to first movement outside a discrete space in an experimental apparatus,,following stimulus,,5.97,s,0.2982,1.3,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68363,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000671,RLA/N,both,104 days to 97 days,18,,CMO:0001037,time to first movement outside a discrete space in an experimental apparatus,,following stimulus,,15.93,s,1.2728,5.4,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68364,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0002074,N:HS,both,104 days to 97 days,20,,CMO:0000960,number of entries into a discrete space in an experimental apparatus,,prompted,,2.6,,0.9257,4.14,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68359,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000663,RHA/N,both,104 days to 97 days,19,,CMO:0000960,number of entries into a discrete space in an experimental apparatus,,prompted,,25.88,,1.2618,5.5,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68360,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",locomotor behavior trait,,RS:0000671,RLA/N,both,104 days to 97 days,18,,CMO:0000960,number of entries into a discrete space in an experimental apparatus,,prompted,,3.17,,0.7071,3.0,MMO:0000302,active avoidance test using a two-way shuttle box apparatus,,0.0,,,,,auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours),68361,auditory stimulus (63 dB) (for 0 hours),visible light stimulus (7 W) (for 0 hours),,,, 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,231,uV,5.0,8.6603,MMO:0000616,electroretinography,cornea,0.0,pVAX2,plasmid delivery,54,days,gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108749,gene transfer using empty plasmid vector pVAX2 (30 ug) ,gene transfer using empty plasmid vector pVAX2 (30 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,199,uV,17.0,29.4449,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,54,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108750,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) ,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,144,uV,29.0,50.2295,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,54,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108751,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,352,uV,26.0,58.1378,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,37,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108701,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),visible light stimulus (3 cd x s/m2) ,, 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,186,uV,23.8,53.2184,MMO:0000616,electroretinography,cornea,0.0,control for age matched plasmid injection,,37,days,control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108702,control condition,,controlled exposure to darkness (for 1 days),visible light stimulus (3 cd x s/m2) ,, 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,114,uV,16.1,36.0007,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,59,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108703,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),visible light stimulus (3 cd x s/m2) ,, 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,24.7,uV,13.8,30.8577,MMO:0000616,electroretinography,cornea,0.0,control for age matched plasmid injection,,59,days,control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108704,control condition,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,475,uV,41.0,91.6788,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,37,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108727,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,352,uV,26.0,58.1378,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,37,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108728,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,135,uV,38.0,84.9706,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,59,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108731,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,114,uV,16.0,35.7771,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,59,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108732,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,87 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,83,uV,7.0,15.6525,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,71,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108735,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,87 days,5,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,110,uV,14.0,31.305,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,71,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108736,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,29.7,uV,11.3,25.2676,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,59,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108729,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,23.8,uV,1.9,3.2909,MMO:0000616,electroretinography,cornea,0.0,pVAX2,plasmid delivery,54,days,gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108746,gene transfer using empty plasmid vector pVAX2 (30 ug) ,gene transfer using empty plasmid vector pVAX2 (30 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,26.7,uV,2.7,4.6765,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,54,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108747,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) ,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,70 days,3,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,20.9,uV,3.7,6.4086,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,54,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108748,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,96.3,uV,10.3,23.0315,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,37,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108725,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,53 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,60.2,uV,8.5,19.0066,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,37,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108726,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,75 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,23.1,uV,4.0,8.9443,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,59,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108730,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,87 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,17.1,uV,3.2,7.1554,MMO:0000616,electroretinography,cornea,0.0,pVAX2-rGDNF,plasmid delivery,71,days,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108733,gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3131,"Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,87 days,5,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,24.5,uV,4.9,10.9567,MMO:0000616,electroretinography,cornea,0.0,,plasmid delivery,71,days,gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) ,108734,gene transfer using empty plasmid vector pVAX2 (30 ug) ,,controlled exposure to darkness (for 1 days),,,visible light stimulus (3 cd x s/m2) 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",eye physiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003729,optokinetic reflex,,,,6,s,0.27,0.7144,MMO:0000754,optokinetic reflex test method,,60.0,,intravitrial injection,98,days,vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) ,109741,vehicle control condition (2 ul) ,,visible light stimulus (25 cd x s/m2) ,,, 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",eye physiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003729,optokinetic reflex,,,,8.2,s,0.4,1.0583,MMO:0000754,optokinetic reflex test method,,60.0,,intravitrial injection,98,days,GSK-812 (2 ul) then visible light stimulus (25 cd x s/m2) ,109742,GSK-812 (2 ul) ,,visible light stimulus (25 cd x s/m2) ,,, 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",cone electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003702,photopic B wave amplitude of ERG waveform,,,,23.1,uV,1.0,2.6458,MMO:0000616,electroretinography,cornea,0.0,,intravitrial injection,98,days,vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) ,109739,vehicle control condition (2 ul) ,,visible light stimulus (25 cd x s/m2) ,,, 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",cone electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003702,photopic B wave amplitude of ERG waveform,,,,28.9,uV,2.5,6.6144,MMO:0000616,electroretinography,cornea,0.0,,intravitrial injection,98,days,GSK-812 (2 ul) then visible light stimulus (25 cd x s/m2) ,109740,GSK-812 (2 ul) ,,visible light stimulus (25 cd x s/m2) ,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,35 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,143.41,uV,12.175,24.35,MMO:0000616,electroretinography,retina,0.0,,hPDLSC transplant,14,days,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109854,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,35 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,95.22,uV,16.19,32.38,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,14,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109856,vehicle control condition (2 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,77 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,13.01,uV,1.845,3.69,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,56,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109862,vehicle control condition (2 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,49 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,204.9,uV,52.13,104.26,MMO:0000616,electroretinography,retina,0.0,,hPDLSC transplant,28,days,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109857,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,49 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,13.93,uV,1.49,2.98,MMO:0000616,electroretinography,retina,0.0,,untreated control,28,days,controlled exposure to darkness (for 12 hours) then visible light stimulus,109858,controlled exposure to darkness (for 12 hours),,visible light stimulus,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,49 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,29.44,uV,7.435,14.87,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,28,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109859,vehicle control condition (2 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,35 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,61.63,uV,15.085,30.17,MMO:0000616,electroretinography,retina,0.0,,untreated control,14,days,controlled exposure to darkness (for 12 hours) then visible light stimulus,109855,controlled exposure to darkness (for 12 hours),,visible light stimulus,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,77 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,45.89,uV,3.225,6.45,MMO:0000616,electroretinography,retina,0.0,,hPDLSC transplant,56,days,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109860,human periodontal ligament-derived stem cells (0.2 x 10E6 cells) ,,controlled exposure to darkness (for 12 hours),visible light stimulus,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,77 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,12.57,uV,1.42,2.84,MMO:0000616,electroretinography,retina,0.0,,untreated control,56,days,controlled exposure to darkness (for 12 hours) then visible light stimulus,109861,controlled exposure to darkness (for 12 hours),,visible light stimulus,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",eye electrophysiology trait,,RS:0000660,RCS/LavRrrc,both,0 days,5,,CMO:0003656,b-wave amplitude of ERG waveform,,scotopic b-wave ERG,,137,uV,18.0,40.2492,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,60,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) ",108664,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (2.5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",eye electrophysiology trait,,RS:0000660,RCS/LavRrrc,both,0 days,5,,CMO:0003656,b-wave amplitude of ERG waveform,,scotopic b-wave ERG,,24,uV,10.0,22.3607,MMO:0000616,electroretinography,cornea,0.0,,,,days,controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) ,108665,controlled exposure to darkness (for 12 hours),,visible light stimulus (2.5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,491,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108653,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,456,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108641,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,387,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ",108646,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,488,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108647,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,338,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108640,vehicle control condition (2 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,397,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ",108652,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,202,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108643,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,154,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ",108648,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,142,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108642,vehicle control condition (2 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,195,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108649,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,173,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ",108654,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (5 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,203,uV,,,MMO:0000616,electroretinography,cornea,0.0,,,,,controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108655,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,51,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ,108644,vehicle control condition (2 ul) ,,controlled visible light condition (30 cd x s/m2) ,visible light stimulus (12 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,75,uV,,,MMO:0000616,electroretinography,cornea,0.0,contralateral control eye,subretinal injection,30,days,controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ,108651,controlled visible light condition (30 cd x s/m2) ,,visible light stimulus (12 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,57,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ",108656,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) ",,controlled visible light condition (30 cd x s/m2) ,visible light stimulus (12 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,90,uV,,,MMO:0000616,electroretinography,cornea,0.0,contralateral control eye,subretinal injection,30,days,controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ,108645,controlled visible light condition (30 cd x s/m2) ,,visible light stimulus (12 cd/m2) ,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,59,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ",108650,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) ",,controlled visible light condition (30 cd x s/m2) ,visible light stimulus (12 cd/m2) ,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,9,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,70,uV,,,MMO:0000616,electroretinography,cornea,0.0,contralateral control eye,subretinal injection,30,days,controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ,108657,controlled visible light condition (30 cd x s/m2) ,,visible light stimulus (12 cd/m2) ,,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,62 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave amplitude ERG,,61,uV,19.5959,48.0,MMO:0000616,electroretinography,cornea,0.0,contralateral control eye,AAV8 injection,60,days,control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) ,108683,control condition,,controlled exposure to darkness (for 12 hours),visible light stimulus (2.5 cd x s/m2) ,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,242 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave amplitude ERG,,223,uV,28.0,56.0,MMO:0000616,electroretinography,cornea,0.0,treated eye,AAV8 injection,240,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.01 cd x s/m2) ",108684,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (0.01 cd x s/m2) ,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,62 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave amplitude ERG,,500,uV,61.2372,150.0,MMO:0000616,electroretinography,cornea,0.0,treated eye,AAV8 injection,60,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) ",108682,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (2.5 cd x s/m2) ,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,62 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave amplitude ERG,,175,uV,14.6969,36.0,MMO:0000616,electroretinography,cornea,0.0,treated eye,AAV8 injection,60,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) ",108680,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) ",,controlled exposure to darkness (for 12 hours),visible light stimulus (2.5 cd x s/m2) ,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,62 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave amplitude ERG,,16,uV,6.9402,17.0,MMO:0000616,electroretinography,cornea,0.0,contralateral control eye,AAV8 injection,60,days,control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) ,108681,control condition,,controlled exposure to darkness (for 12 hours),visible light stimulus (2.5 cd x s/m2) ,, 3129,"Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.",cone electrophysiology trait,,RS:0000652,RCS/N,not specified,242 days,4,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave amplitude ERG,,30,uV,5.5,11.0,MMO:0000616,electroretinography,cornea,0.0,treated eye,AAV8 injection,240,days,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled visible light condition (30 cd/m2) (for 0.1 hours) then visible light stimulus (10 cd x s/m2) and controlled visible light condition (30 cd/m2) ",108685,"gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) ",,controlled visible light condition (30 cd/m2) (for 0.1 hours),visible light stimulus (10 cd x s/m2) ,controlled visible light condition (30 cd/m2) , 3124,"Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.",eye electrophysiology trait,,RS:0000652,RCS/N,not specified,60 days,3,,CMO:0003703,ERG oscillatory potential,,scotopic ocillatory index ERG,,67.6,uV,16.6854,28.9,MMO:0000616,electroretinography,cornea,0.0,,lens puncture,30,days,lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) ,108568,lensotomy,,controlled exposure to darkness (for 1 days),visible light stimulus (100 cd x s/m2) ,, 3124,"Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.",eye electrophysiology trait,,RS:0000652,RCS/N,not specified,60 days,3,,CMO:0003703,ERG oscillatory potential,,photopic ocillatory index,,33.1,uV,2.1939,3.8,MMO:0000616,electroretinography,cornea,0.0,,lens puncture,30,days,lensotomy then controlled visible light exposure (for 0.2 hours) then visible light stimulus (100 cd x s/m2) ,108570,lensotomy,,controlled visible light exposure (for 0.2 hours),visible light stimulus (100 cd x s/m2) ,, 3124,"Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,60 days,3,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,30.5,uV,7.5056,13.0,MMO:0000616,electroretinography,cornea,0.0,,lens puncture,30,days,lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) ,108567,lensotomy,,controlled exposure to darkness (for 1 days),visible light stimulus (100 cd x s/m2) ,, 3124,"Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.",rod electrophysiology trait,,RS:0000652,RCS/N,not specified,60 days,3,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,18.3,uV,4.792,8.3,MMO:0000616,electroretinography,cornea,0.0,,lens puncture,30,days,lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) ,108566,lensotomy,,controlled exposure to darkness (for 1 days),visible light stimulus (100 cd x s/m2) ,, 3124,"Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.",cone electrophysiology trait,,RS:0000652,RCS/N,not specified,60 days,3,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,13.7,uV,2.1939,3.8,MMO:0000616,electroretinography,cornea,0.0,,lens puncture,30,days,lensotomy then controlled visible light exposure (for 0.2 hours) then visible light stimulus (100 cd x s/m2) ,108569,lensotomy,,controlled visible light exposure (for 0.2 hours),visible light stimulus (100 cd x s/m2) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,51.68,uV,12.61,30.8881,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108404,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,327.83,uV,16.41,40.1961,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108405,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,371.67,uV,28.82,70.5943,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108406,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,391.5,uV,33.43,81.8864,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108407,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,411.83,uV,43.52,106.6018,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108408,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,430.17,uV,45.59,111.6722,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108409,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,62.22,uV,18.42,45.1196,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108410,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,460.67,uV,47.48,116.3018,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108411,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,532.5,uV,62.77,153.7545,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108412,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,592.83,uV,68.9,168.7698,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108413,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,638.33,uV,68.2,167.0552,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108414,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,652.5,uV,65.65,160.809,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108415,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,65.42,uV,13.87,33.9744,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108428,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,373.83,uV,17.47,42.7926,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108429,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,382.17,uV,30.52,74.7584,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108430,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,437,uV,33.32,81.617,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108431,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,519.33,uV,29.94,73.3377,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108432,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,594.5,uV,24.04,58.8857,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108433,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,42.97,uV,8.99,22.0209,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108434,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,356.17,uV,23.35,57.1956,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108435,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,399.83,uV,37.74,92.4437,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108436,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,497.33,uV,42.65,104.4707,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108437,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,570.67,uV,21.08,51.6352,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108438,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,621.67,uV,35.23,86.2955,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108439,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,56.16,uV,17.2,42.1312,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108452,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,381.17,uV,37.99,93.0561,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108453,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,440,uV,43.67,106.9692,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108454,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,514.67,uV,47.85,117.2081,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108455,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,587.83,uV,53.2,130.3129,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108456,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,579,uV,50.99,124.8995,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108457,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,49.97,uV,12.07,29.5653,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108458,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,358.5,uV,35.71,87.4713,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108459,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,438.83,uV,24.27,59.4491,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108460,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,516.5,uV,29.8,72.9948,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108461,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,584.5,uV,38.15,93.448,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108462,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,598.67,uV,39.64,97.0978,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108463,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,44.02,uV,13.47,44.6749,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108476,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,270.09,uV,34.35,113.9261,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108477,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,334.55,uV,43.36,143.8089,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108478,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,351.91,uV,47.74,158.3357,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108479,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,410.09,uV,45.37,150.4753,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108481,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,56.72,uV,16.42,54.459,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108482,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,389.91,uV,52.11,172.8293,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108480,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,410.45,uV,48.4,160.5246,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108483,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,466.45,uV,51.69,171.4363,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108484,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,518.55,uV,54.69,181.3862,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108485,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,567.73,uV,56.78,188.318,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108486,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,607.73,uV,58.9,195.3492,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108487,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,71.98,uV,18.54,45.4135,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108500,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,385.17,uV,61.99,151.8439,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108501,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,429.5,uV,66.11,161.9358,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108502,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,485.67,uV,73.15,179.1802,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108503,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,511.83,uV,65.06,159.3638,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108504,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,605.83,uV,62.69,153.5585,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108505,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,101.1,uV,20.75,50.8269,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108506,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,393,uV,65.49,160.4171,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108507,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,533.17,uV,67.99,166.5408,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108508,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,587.17,uV,49.54,121.3477,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108509,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,570.67,uV,53.5,131.0477,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108510,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b wave amplitude ERG,,625,uV,55.4,135.7017,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108511,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,119.08,uV,22.02,53.9378,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108524,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,584.5,uV,55.51,135.9712,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108525,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,644.33,uV,50.52,123.7482,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108526,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,739.67,uV,44.42,108.8063,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108527,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,748.17,uV,64.77,158.6535,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108528,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,800,uV,67.71,165.855,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108529,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,47.53,uV,9.4,23.0252,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108530,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,354,uV,16.81,41.1759,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108531,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,382.33,uV,22.98,56.2893,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108532,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,419,uV,21.83,53.4724,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108533,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,423.33,uV,25.5,62.462,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108534,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,455.17,uV,35.54,87.0549,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108535,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,7.44,uV,1.43,3.7834,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108542,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,83.4,uV,14.8,39.1571,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108543,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,145.24,uV,12.56,33.2306,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108544,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,192,uV,14.42,38.1517,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108545,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,233.29,uV,18.61,49.2374,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108546,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,251.29,uV,19.14,50.6397,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108547,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,10.28,uV,1.69,4.4713,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108554,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,32.75,uV,13.42,35.506,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108555,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,94.13,uV,15.33,40.5594,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108556,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,131.7,uV,16.13,42.676,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108557,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,159.83,uV,21.35,56.4868,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108558,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,179.49,uV,20.75,54.8993,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108559,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,8.81,uV,1.84,4.5071,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108392,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,15.03,uV,4.72,11.5616,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108393,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,78.43,uV,13.51,33.0926,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108394,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,108.63,uV,17.19,42.1067,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108395,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,118.43,uV,17.52,42.9151,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108396,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,143.17,uV,20.27,49.6512,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108397,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,9.73,uV,2.39,5.8543,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108398,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,25.3,uV,2.85,6.981,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108399,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,109.52,uV,22.74,55.7014,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108400,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,161.92,uV,30.48,74.6604,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108401,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,190.68,uV,32.08,78.5796,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108402,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,224.32,uV,34.64,84.8503,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,7,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108403,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,11.22,uV,1.07,2.621,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108416,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,23.02,uV,5.24,12.8353,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108417,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,95.25,uV,7.15,17.5139,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108418,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,162.07,uV,9.02,22.0944,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108419,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,202.5,uV,12.47,30.5451,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108420,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,240.67,uV,14.84,36.3504,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108421,DL-α-aminoadipate (70 ug/ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,7.62,uV,1.56,3.8212,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108422,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,27.7,uV,4.72,11.5616,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108423,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,94.57,uV,13.87,33.9744,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108424,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,149.83,uV,9.83,24.0785,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108425,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,202.33,uV,17.65,43.2335,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108426,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,243.17,uV,24.11,59.0572,MMO:0000616,electroretinography,cornea,0.0,dl-aaa,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108427,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,6.38,uV,1.4,3.4293,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108440,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,25.21,uV,4.23,10.3613,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108441,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,88.5,uV,12.52,30.6676,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108442,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,155.28,uV,13.68,33.509,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108443,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,201.67,uV,18.19,44.5562,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108444,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,216.67,uV,19.46,47.6671,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108445,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,8.38,uV,1.81,4.4336,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108446,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,26.68,uV,7.67,18.7876,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108447,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,78.77,uV,13.41,32.8477,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108448,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,146.78,uV,16.49,40.3921,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108449,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,190.83,uV,21.76,53.3009,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108450,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,218.83,uV,22.09,54.1092,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,30,min,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108451,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,5.17,uV,1.18,3.9136,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108464,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,11.68,uV,2.42,8.0262,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108465,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,71.37,uV,8.23,27.2958,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108466,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,104.17,uV,12.63,41.889,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108467,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,118.51,uV,12.59,41.7563,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108468,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,137.5,uV,12.91,42.8176,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108469,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,12.43,uV,2.29,7.5951,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108470,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,18.46,uV,3.3,10.9449,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108471,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,87.05,uV,8.87,29.4185,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108472,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,144.39,uV,13.24,43.9121,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108473,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,170.91,uV,16.52,54.7906,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108474,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,201.55,uV,19.9,66.0008,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,2,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108475,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,15.46,uV,4.1,10.0429,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108488,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,24.73,uV,6.11,14.9664,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108489,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,80.6,uV,11.3,27.6792,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108490,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,119.33,uV,19.43,47.5936,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108491,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,166.85,uV,19.57,47.9365,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108492,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,188.33,uV,15.56,38.1141,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108493,2-Chloro-5-hydroxyphenylglycine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,13.98,uV,3.06,7.4954,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108494,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,30.66,uV,9.93,24.3234,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108495,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,100.23,uV,12.78,31.3045,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108496,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,145.83,uV,14.32,35.0767,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108497,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,178,uV,12.3,30.1287,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108498,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a wave amplitude ERG,,206,uV,11.62,28.4631,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,10,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108499,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,16.12,uV,3.84,9.406,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108512,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,19.36,uV,3.48,8.5242,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108513,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,208.5,uV,14.36,35.1747,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108516,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,241.17,uV,16.89,41.3719,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108517,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,16.61,uV,4.28,10.4838,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108518,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,16.11,uV,3.41,8.3528,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108519,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,57.63,uV,8.8,21.5555,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108520,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,89.88,uV,11.06,27.0914,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108521,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,124.83,uV,7.26,17.7833,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108522,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,138.93,uV,9.28,22.7313,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + pbs,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108523,DL-α-aminoadipate (70 ug/ul) ,phosphate buffered saline (4 ul) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,11.45,uV,3.5617,9.4234,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108537,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,112.85,uV,11.14,27.2873,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108514,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,172.6,uV,20.12,49.2837,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108515,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,5.86,uV,0.7586,2.007,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108536,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,18.52714286,uV,4.772,12.6256,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108538,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,27.21857143,uV,4.739,12.5383,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108539,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,33.73,uV,9.28,24.5526,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108540,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,36.49,uV,10.37,27.4364,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108541,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,3.13,uV,1.81,4.7888,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108548,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,15.31,uV,2.98,7.8843,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108549,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,19.05,uV,3.75,9.9216,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108550,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,31.22,uV,8.16,21.5893,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108551,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,24.79,uV,7.82,20.6898,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108552,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) ,, 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,31.96,uV,9.73,25.7432,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108553,phosphate buffered saline (4 ul) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) ,,